Top Markets
#1 Black Phoenix Black Phoenix +735.13%
#2 Beam Beam +32.89%
#3 SAFEcoin SAFEcoin +20.16%
#4 TENDIES TENDIES +17.65%
#5 Bless Bless +17.64%
#6 Biconomy Biconomy +16.89%
#7 EfficientFrontier EfficientFrontier +15.58%
#8 pipedog pipedog +15.03%
#9 THORChain THORChain +14.76%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
Black Phoenix Black Phoenix
설정
언어
한국어
통화
USD
테마
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
주식 순위 #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
주가
$36.98
마지막 동기화: 2026-08-26
시가총액
$2.58B
변동 (1일)
-0.67%
변동 (1년)
55.51%
국가
NL
거래 Pharvaris N.V. (PHVS)

카테고리

Healthcare
Pharvaris N.V. (PHVS)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Pharvaris N.V.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Pharvaris N.V.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH